Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
new york
new york blog main
2
×
new york top stories
abbvie
acorda therapeutics
allergan
ampyra
apokyn
apomorphine
bristol-myers squibb
clinical data
dalfampridine
duopa
genfit
gilead sciences
inbrija
intercept pharmaceuticals
ldl-c
liver
liver disease
madrigal pharmaceuticals
mark pruzanski
mylan
nash
nonalcoholic steatohepatitis
obeticholic acid
parkinson's disease
paul matteis
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
stiel
sunovion pharmaceuticals
What
approved
disease
2
×
drug
2
×
new
2
×
acorda
cope
data
episodes
fatty
fda
friday
gets
help
horizon
intercept
known
late
liver
looms
marketed
meant
medications
medicine
nash
nod
nonalcoholic
parkinson’s
patients
rival
steatohepatitis
stop
track
treatment
working
Language
Current search:
drug
×
new
×
" new york blog main "
×
disease
×
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms